Combining the targeting of ERβ by the selective inhibitor fulvestrant with the targeting of TLR4 by CLI-095 may be a potential therapeutic strategy for patients suffering from advanced NSCLC. Here, TLR4 is linked to non-small cell lung carcinoma.